查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2037549

免疫療法市場預測至2034年—按治療方法、給藥途徑、應用、最終用戶、分銷管道和地區分類的全球分析

Immunotherapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Route of Administration, Application, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球免疫療法市場規模將達到 2,463 億美元，並在預測期內以 10.7% 的複合年成長率成長，到 2034 年將達到 5,554 億美元。

免疫療法是指利用和調節人體免疫系統來對抗癌症、自體免疫疾病和感染疾病等疾病的治療方法。這種治療方法包括查核點抑制劑、CAR-T細胞療法、單株抗體和免疫調節劑，它們可以根據需要激活或抑制免疫反應。受癌症發病率上升、突破性監管核准以及個人化醫療方法的普及（與傳統治療方法相比，個人化醫療方法能夠提供更具針對性和更持久的療效）的推動，免疫療法市場正經歷強勁成長。

全球癌症發生率上升和未滿足的需求

隨著全球癌症診斷率持續上升，人們對更有效、毒性較小的傳統化療治療方法的需求日益成長。免疫療法在一些難治性惡性腫瘤（例如進行性黑色素瘤和肺癌）中展現出顯著療效，而傳統治療方法在這些疾病中延長存活期的效果有限。隨著人口老化和癌症篩檢的進步，需要創新療法的患​​者群體也在相應擴大。醫療專業人員越來越重視將免疫療法作為第一線或輔助治療方案，臨床指引也認可其具有持續緩解的潛力。這種持續的臨床需求正在推動免疫療法在多種腫瘤適應症領域的持續研發，並促進其商業性化發展。

嚴重免疫相關不利事件

免疫療法相關的毒性對免疫療法在臨床實踐中的廣泛應用以及患者的依從性構成了重大挑戰。免疫系統活化會引發發炎反應，幾乎影響所有器官系統，包括結腸炎、肺炎、肝炎和內分泌疾病，所有這些都需要專門的治療。這些不利事件通常需要中斷治療、使用高劑量皮質類固醇或永久停藥，限制了特定患者族群的風險效益比。醫療系統不得不投入資金建立專門的監測方案和多學科團隊來應對這些併發症，增加了整體治療成本。此外，免疫相關毒性的不可預測性和嚴重性限制了患者的合格，可能導致一些患有自體自體免疫疾病的患者無法獲得潛在的有效治療。

聯合治療策略和生物標記的開發

將免疫療法與其他治療方法結合的創新方法正在開闢新的治療前景，並擴大可治療的患者群體。與化療、放射線治療、標靶治療或多種免疫查核點抑制劑的策略性聯合應用，展現出協同效應，能夠克服抗藥性機制並提高緩解率。同時，PD-L1表達、腫瘤突變負荷和微衛星不穩定性等預測性生物標記的進步，使得精準篩選患者成為可能，從而在最大限度地提高療效的同時，最大限度地減少不必要的不利事件。這些進展正在加速臨床試驗的開展，產生令人信服的真實世界數據，以支持擴大適應症的監管核准，並為擁有多元化免疫療法產品組合的製藥公司創造巨大的商業性機會。

巨大的價格壓力和贖回挑戰

醫療保健成本不斷上漲以及支付方日益嚴格的審查，威脅著高價免疫療法在關鍵市場的長期商業性可行性。 CAR-T療法的年度治療費用可能超過50萬美元，而查核點抑制劑的價格也十分昂貴，給國家醫療預算和私人保險系統帶來了沉重負擔。 「基於價值的報銷模式」（將已證實的臨床療效與支付掛鉤）的日益普及，為製藥公司的盈利帶來了不確定性。生物相似藥對已上市單株抗體的競爭日益激烈，擠壓了第一代產品的利潤空間。這些財務壓力可能會限制新興市場患者的用藥機會，並限制下一代免疫療法的定價柔軟性，從而可能在臨床需求旺盛的情況下減緩市場擴張。

新冠疫情的影響：

新冠疫情為免疫療法市場帶來了複雜的衝擊。疫情凸顯了免疫系統的重要性，同時也導致診斷延遲。封鎖期間腫瘤篩檢減少，使得更多病例在確診時已晚期，使得包括免疫療法在內的有效治療方法的需求更加迫切。臨床試驗的招募工作受到嚴重影響，許多在臨床實驗遠端醫療的研發進度被延後了6至18個月。然而，疫情也可能透過加速採用分散式臨床試驗模式和遠距醫療進行病患監測，從而提高長期研究效率。此外，為應對新冠疫情而開發的mRNA疫苗技術也驗證了目前正在癌症免疫療法領域研究的平台的有效性，產生了意想不到的協同效應。整體而言，疫情對市場發展軌跡的淨影響為：暫時放緩後，創新加速。

在預測期內，靜脈注射領域預計將佔據最大佔有率。

預計在預測期內，靜脈注射途徑將佔據最大的市場佔有率。這反映了其作為大多數單株抗體、查核點抑制劑和細胞療法標準給藥方式的既定地位。直接靜脈輸注可確保藥物的完全生物利用度，並可精確控制輸注速率，這對於控制免疫療法通用的輸注相關反應至關重要。醫院和診所的輸液中心配備齊全，可在專家的監督下進行這些治療，並能立即應對不利事件。鑑於靜脈注射在眾多已通過核准的適應症中具有廣泛的臨床療效，以及新型靜脈注射免疫療法的不斷研發，預計在整個預測期內，這種給藥途徑的主導地位將穩固確立。

在預測期內，血液腫瘤領域預計將呈現最高的複合年成長率。

在預測期內，血液系統惡性腫瘤領域預計將呈現最高的成長率，這主要得益於CAR-T細胞療法和特異性骨髓惡性腫瘤的雙特異性抗體製劑的突破性進展。白血病、淋巴瘤和多發性骨髓瘤等疾病對免疫療法的反應極為良好，有些患者甚至在對所有常規治療方法均無反應後，仍能達到完全緩解。 CAR-T產品在早期治療方案中的核准擴大，以及現成的異基因細胞療法的出現，在提高患者治療可及性的同時，也縮短了生產等待時間。此外，能夠誘導T細胞攻擊腫瘤標靶的新型雙特異性抗體正在改變復發或難治性血液系統惡性腫瘤的治療模式，為此高成長應用領域注入了持續動力。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於其強大的研發基礎設施、有利的監管環境以及集中的藥物創新。美國擁有許多領先的免疫療法研發公司，並擁有全球最大的臨床試驗生態系統，因此能夠快速開發和核准產品。強大的智慧財產權保護和高定價趨勢正在推動對下一代平台的持續投資。廣泛的保險覆蓋，包括聯邦醫療保險（Medicare）和私人保險公司，確保了患者即使面臨高昂的治療費用也能獲得治療。該地區成熟的癌症治療基礎設施，包括配備齊全、能夠處理免疫療法相關不利事件的專業癌症中心，將在整個預測期內進一步鞏固其在北美市場的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健支出不斷成長、患者群體龐大以及監管體系的快速現代化。中國正崛起為CAR-T療法研究領域的全球領導者，許多國產產品已進入臨床開發階段並獲得國內核准。印度不斷擴大的生物相似藥生產能力正使其龐大的人口能夠負擔得起免疫療法。日本和韓國擁有先進的醫療保健體系，能夠在獲得監管機構核准後迅速引進創新治療方法。政府為促進國內生物技術創新所做的努力，以及透過技術轉移進行的國際夥伴關係，正加速市場成熟。隨著成本的降低和在地化生產帶來的可及性提升，亞太地區將成為免疫療法領域成長最快的區域市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球免疫療法市場：依治療方法

  • 單株抗體
    • 未修飾的單株抗體
    • 偶聯單株抗體
    • 雙特異性抗體
  • 免疫查核點抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
    • CTLA-4抑制劑
    • LAG-3抑制劑
  • 癌症疫苗
    • 預防性疫苗
    • 治療性疫苗
  • 細胞療法
    • CAR-T細胞療法
    • TCR療法
    • NK細胞療法
  • 基於細胞激素的治療方法
    • 白細胞介素
    • 干擾素
  • 溶瘤病毒療法
  • 其他治療方法

第6章：全球免疫療法市場：依給藥途徑分類

  • 靜脈
  • 皮下
  • 口服
  • 肌肉內部

第7章 全球免疫療法市場：依應用領域分類

  • 癌症
    • 肺癌
    • 乳癌
    • 結腸癌
    • 黑色素瘤
    • 攝護腺癌
    • 血癌
    • 其他癌症
  • 自體免疫疾病
  • 感染疾病
  • 發炎性疾病
  • 其他用途

第8章 全球免疫療法市場：以最終用戶分類

  • 醫院
  • 診所
  • 癌症研究中心
  • 門診手術中心

第9章 全球免疫療法市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章 全球免疫療法市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Amgen Inc.
  • AbbVie Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Biogen Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: SMRC35964

According to Stratistics MRC, the Global Immunotherapy Market is accounted for $246.3 billion in 2026 and is expected to reach $555.4 billion by 2034 growing at a CAGR of 10.7% during the forecast period. Immunotherapy refers to treatments that harness and modulate the body's immune system to fight diseases, including cancer, autoimmune disorders, and infectious conditions. This therapeutic approach encompasses checkpoint inhibitors, CAR-T cell therapies, monoclonal antibodies, and immune modulators that either activate or suppress immune responses as clinically required. The market is experiencing robust expansion driven by rising cancer incidence, breakthrough regulatory approvals, and growing adoption of personalized medicine approaches that offer targeted, durable responses compared to conventional therapies.

Market Dynamics:

Driver:

Rising global cancer incidence and unmet medical needs

The escalating number of cancer diagnoses worldwide continues to fuel demand for more effective and less toxic treatment alternatives to traditional chemotherapy. Immunotherapies have demonstrated remarkable efficacy in previously difficult-to-treat malignancies, including advanced melanoma and lung cancer, where conventional options offered limited survival benefits. As the global population ages and cancer screening improves, the patient pool requiring innovative treatments expands correspondingly. Healthcare providers increasingly prioritize immunotherapies as first-line or adjunctive treatments, supported by clinical guidelines that recognize their potential for durable remissions. This persistent clinical need creates sustained momentum for continued research, development, and commercial expansion across multiple oncology indications.

Restraint:

Severe immune-related adverse events

Treatment-associated toxicities pose significant challenges to broader immunotherapy adoption and patient compliance in clinical practice. Immune system activation can lead to inflammatory reactions affecting virtually any organ system, including colitis, pneumonitis, hepatitis, and endocrinopathies that require specialized management. These adverse events often necessitate treatment interruptions, high-dose corticosteroids, or permanent discontinuation, limiting the risk-benefit profile for certain patient populations. Healthcare systems must invest in specialized monitoring protocols and multidisciplinary care teams to manage these complications, increasing overall treatment costs. The unpredictability and severity of immune-related toxicities also constrain patient eligibility, excluding individuals with pre-existing autoimmune conditions from potentially beneficial therapies.

Opportunity:

Combination therapy strategies and biomarker development

Innovative approaches combining immunotherapies with other modalities are opening new therapeutic frontiers and expanding addressable patient populations. Strategic pairings with chemotherapy, radiation, targeted therapies, or multiple immune checkpoint inhibitors have demonstrated synergistic effects, overcoming resistance mechanisms and improving response rates. Concurrent advances in predictive biomarkers, including PD-L1 expression, tumor mutational burden, and microsatellite instability, enable precise patient selection, maximizing efficacy while minimizing unnecessary exposure to adverse events. These developments are accelerating clinical trial activity and generating compelling real-world evidence that supports regulatory approvals for expanded indications, creating substantial commercial opportunities for pharmaceutical companies with diversified immunotherapy portfolios.

Threat:

Intense pricing pressure and reimbursement challenges

Escalating healthcare costs and payer scrutiny threaten the long-term commercial viability of premium-priced immunotherapy treatments across major markets. Annual treatment costs for CAR-T therapies can exceed half a million dollars, while checkpoint inhibitors carry substantial price tags that strain national health budgets and private insurance systems. Value-based reimbursement models are gaining traction, linking payment to demonstrated clinical outcomes, which introduces revenue uncertainty for manufacturers. Biosimilar competition for established monoclonal antibodies is intensifying, compressing margins for first-generation products. These financial pressures may limit patient access in emerging economies and constrain pricing flexibility for next-generation immunotherapies, potentially slowing market expansion despite strong clinical demand.

Covid-19 Impact:

The COVID-19 pandemic created complex disruptions for immunotherapy markets, simultaneously delaying diagnoses while highlighting immune system importance. Oncology screening declines during lockdowns led to later-stage diagnoses, increasing urgency for effective treatments including immunotherapies. Clinical trial enrollments faced significant interruptions, postponing numerous investigational product timelines by six to eighteen months. However, the pandemic accelerated adoption of decentralized trial models and telemedicine for patient monitoring, which may benefit long-term study efficiency. mRNA vaccine technologies developed for COVID-19 also validated platforms now being explored for cancer immunotherapies, creating unexpected cross-fertilization. Overall, the pandemic's net effect on market trajectory has been a temporary slowdown followed by accelerated innovation.

The Intravenous segment is expected to be the largest during the forecast period

The Intravenous segment is expected to account for the largest market share during the forecast period, reflecting its established role as the standard delivery method for most monoclonal antibodies, checkpoint inhibitors, and cell-based therapies. Direct venous access ensures complete bioavailability and allows precise control over infusion rates, which is critical for managing infusion-related reactions common to immunotherapeutic agents. Hospital and clinic-based infusion centers are well-equipped to administer these treatments under professional supervision, enabling immediate intervention for adverse events. The extensive clinical validation of intravenous administration across numerous approved indications, combined with ongoing development of new IV-based immunotherapies, solidifies this route's dominance throughout the forecast timeline.

The Blood Cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Blood Cancer segment is predicted to witness the highest growth rate, driven by revolutionary advances in CAR-T cell therapies and bispecific antibody constructs specifically targeting hematologic malignancies. Conditions including leukemia, lymphoma, and multiple myeloma have demonstrated exceptional responsiveness to immunotherapy approaches, with some patients achieving complete remission after failing all conventional treatments. The expanding approval of CAR-T products for earlier treatment lines and the emergence of off-the-shelf allogeneic cell therapies are broadening patient access while reducing manufacturing wait times. Additionally, novel bispecific antibodies engaging T-cells against cancer targets are transforming treatment paradigms for relapsed or refractory blood cancers, creating sustained momentum for this high-growth application segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by robust research infrastructure, favorable regulatory pathways, and concentrated pharmaceutical innovation. The United States hosts the headquarters of most leading immunotherapy developers and maintains the world's largest clinical trial ecosystem, enabling rapid product development and approval. Strong intellectual property protections and premium pricing dynamics incentivize continued investment in next-generation platforms. Extensive insurance coverage, including Medicare and private payers, supports patient access despite high treatment costs. The region's mature oncology care infrastructure, with specialized cancer centers equipped to manage immunotherapy-related toxicities, further reinforces North America's dominant market position throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by increasing healthcare expenditure, large patient populations, and rapid regulatory modernization. China has emerged as a global leader in CAR-T research, with numerous domestic products advancing through clinical development and receiving national approvals. India's growing biosimilar manufacturing capabilities are making immunotherapies more affordable for its vast population. Japan and South Korea maintain sophisticated healthcare systems that rapidly adopt innovative therapies following regulatory endorsement. Government initiatives promoting domestic biotechnology innovation, combined with international partnerships for technology transfer, are accelerating market maturation. As local manufacturing reduces costs and expands accessibility, Asia Pacific becomes the fastest-growing regional market for immunotherapies.

Key players in the market

Some of the key players in Immunotherapy Market include Bristol Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, Amgen Inc., AbbVie Inc., Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Biogen Inc. and Takeda Pharmaceutical Company Limited.

Key Developments:

In April 2026, Roche's subsidiary Genentech moved closer to Phase 3 readouts for its pumitamig combination trials, a novel-novel approach being explored in partnership with other biotech leaders to address resistant tumor types.

In April 2026, Johnson & Johnson received U.S. FDA approval for the combination of TECVAYLI and DARZALEX FASPRO as a second-line treatment for relapsed/refractory multiple myeloma.

In March 2026, Bristol Myers Squibb announced that the European Medicines Agency (EMA) and the U.S. FDA expanded approvals for Opdivo (nivolumab), transforming the treatment paradigm for classical Hodgkin lymphoma by allowing its use in broader patient populations.

In January 2026, Novartis announced that the U.S. FDA granted Breakthrough Therapy designation to ianalumab for Sjogren's disease, a progressive autoimmune condition with a high risk of lymphoma.

Therapy Types Covered:

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Cell-based Therapies
  • Cytokine-based Therapies
  • Oncolytic Virus Therapy
  • Other Therapy Types

Route of Administrations Covered:

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Applications Covered:

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Inflammatory Diseases
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Cancer Research Centers
  • Ambulatory Surgical Centers

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Immunotherapy Market, By Therapy Type

  • 5.1 Monoclonal Antibodies
    • 5.1.1 Naked Monoclonal Antibodies
    • 5.1.2 Conjugated Monoclonal Antibodies
    • 5.1.3 Bispecific Antibodies
  • 5.2 Immune Checkpoint Inhibitors
    • 5.2.1 PD-1 Inhibitors
    • 5.2.2 PD-L1 Inhibitors
    • 5.2.3 CTLA-4 Inhibitors
    • 5.2.4 LAG-3 Inhibitors
  • 5.3 Cancer Vaccines
    • 5.3.1 Preventive Vaccines
    • 5.3.2 Therapeutic Vaccines
  • 5.4 Cell-based Therapies
    • 5.4.1 CAR-T Cell Therapy
    • 5.4.2 TCR Therapy
    • 5.4.3 NK Cell Therapy
  • 5.5 Cytokine-based Therapies
    • 5.5.1 Interleukins
    • 5.5.2 Interferons
  • 5.6 Oncolytic Virus Therapy
  • 5.7 Other Therapy Types

6 Global Immunotherapy Market, By Route of Administration

  • 6.1 Intravenous
  • 6.2 Subcutaneous
  • 6.3 Oral
  • 6.4 Intramuscular

7 Global Immunotherapy Market, By Application

  • 7.1 Cancer
    • 7.1.1 Lung Cancer
    • 7.1.2 Breast Cancer
    • 7.1.3 Colorectal Cancer
    • 7.1.4 Melanoma
    • 7.1.5 Prostate Cancer
    • 7.1.6 Blood Cancer
    • 7.1.7 Other Cancer
  • 7.2 Autoimmune Diseases
  • 7.3 Infectious Diseases
  • 7.4 Inflammatory Diseases
  • 7.5 Other Applications

8 Global Immunotherapy Market, By End User

  • 8.1 Hospitals
  • 8.2 Clinics
  • 8.3 Cancer Research Centers
  • 8.4 Ambulatory Surgical Centers

9 Global Immunotherapy Market, By Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Retail Pharmacies
  • 9.3 Online Pharmacies

10 Global Immunotherapy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Bristol Myers Squibb Company
  • 13.2 Merck & Co. Inc.
  • 13.3 Roche Holding AG
  • 13.4 Novartis AG
  • 13.5 Pfizer Inc.
  • 13.6 Johnson & Johnson
  • 13.7 AstraZeneca plc
  • 13.8 Amgen Inc.
  • 13.9 AbbVie Inc.
  • 13.10 Sanofi SA
  • 13.11 GlaxoSmithKline plc
  • 13.12 Eli Lilly and Company
  • 13.13 Regeneron Pharmaceuticals Inc.
  • 13.14 Gilead Sciences Inc.
  • 13.15 Biogen Inc.
  • 13.16 Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1 Global Immunotherapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Immunotherapy Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Immunotherapy Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 4 Global Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2023-2034) ($MN)
  • Table 5 Global Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2023-2034) ($MN)
  • Table 6 Global Immunotherapy Market Outlook, By Bispecific Antibodies (2023-2034) ($MN)
  • Table 7 Global Immunotherapy Market Outlook, By Immune Checkpoint Inhibitors (2023-2034) ($MN)
  • Table 8 Global Immunotherapy Market Outlook, By PD-1 Inhibitors (2023-2034) ($MN)
  • Table 9 Global Immunotherapy Market Outlook, By PD-L1 Inhibitors (2023-2034) ($MN)
  • Table 10 Global Immunotherapy Market Outlook, By CTLA-4 Inhibitors (2023-2034) ($MN)
  • Table 11 Global Immunotherapy Market Outlook, By LAG-3 Inhibitors (2023-2034) ($MN)
  • Table 12 Global Immunotherapy Market Outlook, By Cancer Vaccines (2023-2034) ($MN)
  • Table 13 Global Immunotherapy Market Outlook, By Preventive Vaccines (2023-2034) ($MN)
  • Table 14 Global Immunotherapy Market Outlook, By Therapeutic Vaccines (2023-2034) ($MN)
  • Table 15 Global Immunotherapy Market Outlook, By Cell-based Therapies (2023-2034) ($MN)
  • Table 16 Global Immunotherapy Market Outlook, By CAR-T Cell Therapy (2023-2034) ($MN)
  • Table 17 Global Immunotherapy Market Outlook, By TCR Therapy (2023-2034) ($MN)
  • Table 18 Global Immunotherapy Market Outlook, By NK Cell Therapy (2023-2034) ($MN)
  • Table 19 Global Immunotherapy Market Outlook, By Cytokine-based Therapies (2023-2034) ($MN)
  • Table 20 Global Immunotherapy Market Outlook, By Interleukins (2023-2034) ($MN)
  • Table 21 Global Immunotherapy Market Outlook, By Interferons (2023-2034) ($MN)
  • Table 22 Global Immunotherapy Market Outlook, By Oncolytic Virus Therapy (2023-2034) ($MN)
  • Table 23 Global Immunotherapy Market Outlook, By Other Therapy Types (2023-2034) ($MN)
  • Table 24 Global Immunotherapy Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 25 Global Immunotherapy Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 26 Global Immunotherapy Market Outlook, By Subcutaneous (2023-2034) ($MN)
  • Table 27 Global Immunotherapy Market Outlook, By Oral (2023-2034) ($MN)
  • Table 28 Global Immunotherapy Market Outlook, By Intramuscular (2023-2034) ($MN)
  • Table 29 Global Immunotherapy Market Outlook, By Application (2023-2034) ($MN)
  • Table 30 Global Immunotherapy Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 31 Global Immunotherapy Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 32 Global Immunotherapy Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 33 Global Immunotherapy Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 34 Global Immunotherapy Market Outlook, By Melanoma (2023-2034) ($MN)
  • Table 35 Global Immunotherapy Market Outlook, By Prostate Cancer (2023-2034) ($MN)
  • Table 36 Global Immunotherapy Market Outlook, By Blood Cancer (2023-2034) ($MN)
  • Table 37 Global Immunotherapy Market Outlook, By Other Cancer (2023-2034) ($MN)
  • Table 38 Global Immunotherapy Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
  • Table 39 Global Immunotherapy Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 40 Global Immunotherapy Market Outlook, By Inflammatory Diseases (2023-2034) ($MN)
  • Table 41 Global Immunotherapy Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 42 Global Immunotherapy Market Outlook, By End User (2023-2034) ($MN)
  • Table 43 Global Immunotherapy Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 44 Global Immunotherapy Market Outlook, By Clinics (2023-2034) ($MN)
  • Table 45 Global Immunotherapy Market Outlook, By Cancer Research Centers (2023-2034) ($MN)
  • Table 46 Global Immunotherapy Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 47 Global Immunotherapy Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 48 Global Immunotherapy Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 49 Global Immunotherapy Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 50 Global Immunotherapy Market Outlook, By Online Pharmacies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.